Study of AMG531 (Romiplostim) in Patients With Aplastic Anemia

Summary

To evaluate the hematological responses based on the response assessment criteria defined in this study (the 531-004 response assessment criteria) when AMG531 is subcutaneously (SC)-administered with ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

Timeline

Start

2019-12-03

Primary completion

2021-10-07

Completion

2021-10-29

Drugs

Indications